Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C
View/ Open
Author
Xiao, Fei
Fofana, Isabel
Thumann, Christine
Mailly, Laurent
Alles, Roxane
Robinet, Eric
Meyer, Nicolas
Schaeffer, Mickaël
Habersetzer, François
Doffoël, Michel
Leyssen, Pieter
Neyts, Johan
Zeisel, Mirjam B
Baumert, Thomas F
Note: Order does not necessarily reflect citation order of authors.
Published Version
https://doi.org/10.1136/gutjnl-2013-306155Metadata
Show full item recordCitation
Xiao, F., I. Fofana, C. Thumann, L. Mailly, R. Alles, E. Robinet, N. Meyer, et al. 2015. “Synergy of entry inhibitors with direct-acting antivirals uncovers novel combinations for prevention and treatment of hepatitis C.” Gut 64 (3): 483-494. doi:10.1136/gutjnl-2013-306155. http://dx.doi.org/10.1136/gutjnl-2013-306155.Abstract
Objective: Although direct-acting antiviral agents (DAAs) have markedly improved the outcome of treatment in chronic HCV infection, there continues to be an unmet medical need for improved therapies in difficult-to-treat patients as well as liver graft infection. Viral entry is a promising target for antiviral therapy. Design: Aiming to explore the role of entry inhibitors for future clinical development, we investigated the antiviral efficacy and toxicity of entry inhibitors in combination with DAAs or other host-targeting agents (HTAs). Screening a large series of combinations of entry inhibitors with DAAs or other HTAs, we uncovered novel combinations of antivirals for prevention and treatment of HCV infection. Results: Combinations of DAAs or HTAs and entry inhibitors including CD81-, scavenger receptor class B type I (SR-BI)- or claudin-1 (CLDN1)-specific antibodies or small-molecule inhibitors erlotinib and dasatinib were characterised by a marked and synergistic inhibition of HCV infection over a broad range of concentrations with undetectable toxicity in experimental designs for prevention and treatment both in cell culture models and in human liver-chimeric uPA/SCID mice. Conclusions: Our results provide a rationale for the development of antiviral strategies combining entry inhibitors with DAAs or HTAs by taking advantage of synergy. The uncovered combinations provide perspectives for efficient strategies to prevent liver graft infection and novel interferon-free regimens.Other Sources
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4345833/pdf/Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351255
Collections
- HMS Scholarly Articles [17917]
Contact administrator regarding this item (to report mistakes or request changes)